Cargando…
Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies
Since the approval of the first immune checkpoint inhibitor (ICI) 9 years ago, ICI-therapy have revolutionized cancer treatment. Lately, antibodies blocking the interaction of programmed cell death protein (PD-1) and ligand (PD-L1) are gaining momentum as a cancer treatment, with multiple agents and...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887301/ https://www.ncbi.nlm.nih.gov/pubmed/33614750 http://dx.doi.org/10.3389/fcvm.2021.619650 |